Daniel Joseph Dorgan, MD
Associate Professor of Clinical Medicine (Pulmonary, Allergy and Critical Care)
Associate Program Director, Adult Cystic Fibrosis Program, University of Pennsylvania
Program Director, Adult Primary Ciliary Dyskinesia Program, University of Pennsylvania
Site Director, Therapeutics Development Network (Site Principal Investigator), Adult Cystic Fibrosis Program, University of Pennsylvania
Director, Advanced Lung Disease Clinical Research Group, University of Pennsylvania
Vice Chief of Clinical Affairs, Division of Pulmonary, Allergy, and Critical Care Medicine
University of Pennsylvania
Department: Medicine
Contact information
Harron Lung Center
3400 Civic Center Blvd
Philadelphia, PA 19104
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-662-3202
Fax: 215-349-8432
Fax: 215-349-8432
Education:
BS (Biochemistry)
Michigan State University, 1998.
MD
University of Michigan, 2004.
Permanent linkBS (Biochemistry)
Michigan State University, 1998.
MD
University of Michigan, 2004.
Description of Clinical Expertise
Cystic FibrosisBronchiectasis
Ciliary Dyskinesia
Pulmonary Mycobacterial Infections
Chronic Pulmonary Infections
Description of Research Expertise
Cystic FibrosisBronchiectasis
Ciliary Dyskinesia
Pulmonary Mycobacterial Infections
Selected Publications
Giannini HM, Lee C, Baston C, Dorgan D.: A Diagnostic Sequence. N Engl J Med 388: 1702-1707, May 2023.Hong G, Daniel SG, Lee JJ, Bittinger K, Glaser L, Mattei LM, Dorgan DJ, Hadjiliadis D, Kawut SM, Collman RG.: Distinct community structures of the fungal microbiome and respiratory health in adults with cystic fibrosis. J Cyst Fibros 2023.
Rowe SM, Zuckerman JB, Dorgan D, Lascano J, McCoy K, Jain M, Schechter MS, Lommatzsch S, Indihar V, Lechtzin N, McBennett K, Callison C, Brown C, Liou TG, MacDonald KD, Nasr SZ, Bodie S, Vaughn M, Meltzer EB, Barbier AJ.: Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study. J Cyst Fibros 2023.
O'Dea AL, Feng R, Glaser LJ, Kubrak C, Rubenstein RC, Dorgan DJ, Hadjiliadis D, Kawut SM, Hong G.: The Clinical Association between Aspergillus fumigatus and Respiratory Outcomes in Adolescents and Adults with Cystic Fibrosis. Ann Am Thorac Soc 2023.
Lee IK, Jacome DA, Cho JK, Tu V, Young AJ, Dominguez T, Northrup JD, Etersque JM, Lee HS, Ruff A, Aklilu O, Bittinger K, Glaser LJ, Dorgan D, Hadjiliadis D, Kohli RM, Mach RH, Mankoff DA, Doot RK, Sellmyer MA: Imaging sensitive and drug-resistant bacterial infection with [11C]-trimethoprim. The Journal of Clinical Investigation 132(18): e156679, Sep 2022.
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM, for the PROMISE Study group: Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. American Journal of Respiratory and Critical Care Medicine 205(5): 529-539, Mar 2022.
Mayer-Hamblett N, Ratjen F, Russell R, Donaldson SH, Riekert KA Sawicki GS, Odem-Davis K, Young JK, Rosenbluth D, Taylor-Cousar JL, Goss CH, Retsch-Bogart G, Clancy JP, Genatossio A, O’Sullivan BP, Berlinski A, Millard SL, Omlor G, Wyatt CA, Moffett K, Nichols DP, Gifford AH, on behalf of the SIMPLIFY Study Group: Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials. The Lancet Respiratory Medicine 2022 Notes: Online first, DOI:https://doi.org/10.1016/S2213-2600(22)00434-9.
Goss CH, Heltshe SL, West NE, Skalland M, Sanders DB, Jain R, Barto TL, Fogarty B, Marshall BC, VanDevanter DR, Flume PA, on Behalf of the STOP2 Investigators: A Randomized Trial of Antimicrobial Duration for Cystic Fibrosis Pulmonary Exacerbation Treatment. American Journal of Respiratory and Critical Care Medicine 65(1): 1295-1305, Dec 2021.
Harruff EE, Kil J, Ortiz MGT, Dorgan D, Jain R, Poth EA, Fifer RC, Kim YJM, Shoup AG, Flume PA: Ototoxicity in Cystic Fibrosis Patients Receiving Intravenous Tobramycin for Acute Pulmonary Exacerbation. Journal of Cystic Fibrosis 20(2): 288-294, Mar 2021.
Douglas JE, Civantos AM, Locke TB, Sweis AM, Hadjiliadis D, Hong G, Dorgan D, Kohanski MA, Palmer JN, Adappa ND: Impact of Novel CFTR Modulator on Sinonasal Quality of Life in Adult Patients with Cystic Fibrosis. International Forum of Allergy & Rhinology 11(2): 201-203, Feb 2021.